Recent advances in chronic lymphocytic leukemia therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Uhm, Jieun | - |
dc.date.accessioned | 2021-08-02T09:25:59Z | - |
dc.date.available | 2021-08-02T09:25:59Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/9684 | - |
dc.description.abstract | Chronic lymphocytic leukemia is a genetically heterogeneous disease, and a complex set of genetic alterations is associated with its pathogenesis. CLL is the most common leukemia in the western countries, whereas it is rare in Asia, including Korea. The prognostic models integrate the traditional staging systems developed by Rai et al. and Binet et al. with biochemical and genetic markers. With the advent of molecular biology, a variety of targeted agents, including anti-CD20 antibodies, inhibitors of BCR signaling pathway, and BCL-2 inhibitors, have been introduced, which has changed the landscape of CLL treatment greatly. This review will focus on the risk stratification and the management of CLL in the era of novel small molecules. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC HEMATOLOGY | - |
dc.title | Recent advances in chronic lymphocytic leukemia therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Uhm, Jieun | - |
dc.identifier.doi | 10.5045/br.2020.S012 | - |
dc.identifier.scopusid | 2-s2.0-85090368648 | - |
dc.identifier.wosid | 000556038900012 | - |
dc.identifier.bibliographicCitation | BLOOD RESEARCH, v.55, pp.72 - 82 | - |
dc.relation.isPartOf | BLOOD RESEARCH | - |
dc.citation.title | BLOOD RESEARCH | - |
dc.citation.volume | 55 | - |
dc.citation.startPage | 72 | - |
dc.citation.endPage | 82 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002612138 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | PREVIOUSLY UNTREATED PATIENTS | - |
dc.subject.keywordPlus | GENE MUTATION STATUS | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | PROGNOSTIC INDEX | - |
dc.subject.keywordPlus | INITIAL THERAPY | - |
dc.subject.keywordPlus | 17P DELETION | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | IBRUTINIB | - |
dc.subject.keywordAuthor | Chronic lymphocytic leukemia | - |
dc.subject.keywordAuthor | Prognostic models | - |
dc.subject.keywordAuthor | Immunochemotherapy TP53 | - |
dc.identifier.url | https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2020.S012 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.